Description
A cell-permeable prodrug of SB 201076; inhibits fatty acid and cholesterol synthesis in HepG2 cells in a concentration-dependent manner; reduces plasma levels of the lipoproteins VLDL, LDL, and HDL by 21, 40, and 22%, respectively, in dogs when administered orally at a dose of 25 mg/kg; reduces VLDL synthesis and plasma cholesterol and triglyceride levels in rats in a dose-dependent manner
Formal name: (3R,5S)-rel-5-[6-(2,4-dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid
Synonyms:
Molecular weight: 389.3
CAS: 154566-12-8
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias